Trial intelligence / Profile preview

RELVAR ELLIPTA versus SERETIDE ACCUHALER/DISKUS versus fluticasone propionate in controlled persistent asthma

2014-002253-19Phase 3Completed

Sponsor: GSK
Start: Oct 2014
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
Countries: 1

Overview

Phase 3, randomised, double-blind trial in persistent asthma comparing RELVAR ELLIPTA once daily, SERETIDE ACCUHALER/DISKUS twice daily and Fluticasone propionate twice daily (3 arms). Primary endpoint: Change from baseline in clinic visit evening pre-bronchodilator, predose FEV1 at Week 24. Started Oct 2014; status: completed.

Drugs

fluticasone propionate + vilanterolsalmeterol + fluticasonefluticasone propionate

Conditions

persistent asthma

Beyond the preview

Go deeper on 2014-002253-19.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-002253-19.